Alumis LUMUS Phase 2b misses primary endpoint in SLE; IFNGS-high subgroup shows robust responses

ALUMIS INC.

LUMUS Phase 2b (n=408) did not meet primary endpoint BICLA at Week 48 in overall SLE population.
Prespecified IFNGS-high subgroup showed robust responses on BICLA, CLASI-50, SRI-4, and LLDAS.
Dose-dependent target engagement with maximal suppression at 40mg BID; no new safety signals observed.
Alumis plans regulatory engagement to discuss Phase 3 development for envudeucitinib in SLE.
NDA submission for envudeucitinib in moderate-to-severe plaque psoriasis remains on track for 4Q 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.